Atlas
Back to RCM
Legal / Service Provider·RCM

Geoffrey C. Cockrell

Partner, healthcare private equity and M&A (immediate past chair of the firm's private equity group) at McGuireWoods LLP

Chicago, Illinois

GC
Why they matter

Runs the deal bench for healthcare provider-services roll-ups: he papers the PPM, DSO and billing-compliance structures that decide whether an RCM-dependent platform survives diligence.

Background

Geoff Cockrell is a partner at McGuireWoods in Chicago and the immediate past chair of the firm's private equity group, which he led for over a decade; he also formerly served on the firm's Board of Partners. His M&A and financing practice represents private equity sponsors, strategic buyers and sellers, with a primary focus on healthcare provider services transactions across ophthalmology, dental, dermatology, physical therapy, behavioral health and fertility. He holds a JD from Notre Dame Law School (magna cum laude, 1997) and a BA in business/economics from Wheaton College (1993), and is a Chambers USA-ranked leading lawyer for Private Equity Buyouts in Illinois.

Notable deals

  • 2020
    Represented MoonSail Capital and Plenary Partners in their strategic partnership with Arbor Centers for EyeCare and Chicago Eye Institute to form Ocular Partners, a physician-led eye care platform for greater Chicago.
  • 2019
    Represented BelHealth Investment Partners and its dermatology platform NavaDerm in the add-on acquisition of Laser & Skin Surgery Center of New York, a leading cosmetic and Mohs dermatology practice.
  • 2022
    Named to Crain's Chicago Business' Notable Gen X Leaders in Accounting, Consulting & Law, cited as leader of McGuireWoods' private equity practice and a member of its board of partners.
  • 2026
    Led the banker-focused panel at McGuireWoods' Healthcare Private Equity and Finance Conference in Chicago (April 29-30), one of the largest healthcare PE gatherings in the US, which he co-hosts annually.

Call-prep brief

Background

  • Chicago-based McGuireWoods partner; immediate past chair of the firm's private equity group (led it for over a decade) and a former member of the Board of Partners.
  • JD, Notre Dame Law School (magna cum laude, 1997); BA, Wheaton College (1993).
  • Repeat counsel to lower-middle-market healthcare sponsors: Sheridan Capital, Shore Capital, Ridgemont, Linden, LLR, Audax, Silver Oak, BelHealth, Chicago Pacific Founders.

Current focus

  • Physician practice management and DSO consolidation: ophthalmology (Ocular Partners, Long Island Vision), dental (Chicagoland Smile Group, Smile Doctors), dermatology (NavaDerm), physical therapy, behavioral health and fertility.
  • Platform formation and add-on sequencing, secondary sponsor-to-sponsor sales, and independent-sponsor structures.

What they care about

  • Whether a roll-up is genuinely physician-led, and whether the back office (billing, coding, collections) survives payor and regulatory scrutiny. His July 2026 podcast with Wiks Moffat framed compliance as a deal asset rather than a cost center, surfacing missed revenue post-close.
  • Buyer quality and what defines an "A-caliber" asset in a thawing provider-services market.

Recent moves

  • Hosts *The Corner Series* and writes The Healthcare Investor; co-hosts the annual McGuireWoods Healthcare PE and Finance Conference (led the banker panel, April 2026).

Potential sensitivities

  • He is outside counsel, not a principal: he will not name live mandates, unannounced deals, or client economics, and a conflicts check may precede substantive discussion. Avoid asking him to rank sponsors he serves.

Questions to ask

  1. In provider-services diligence, what RCM red flags kill a deal versus get priced into the QoE?
  2. Where are payor mix and coding-integrity issues showing up in secondary sales of PPM platforms?
  3. Which structures are holding up under corporate-practice-of-medicine scrutiny in your active states?

Outreach draft

Subject
Provider-services RCM diligence: 20 minutes?
Geoff. I lead diligence on healthcare provider-services platforms, and revenue cycle is where our theses keep breaking. Your Corner Series episode on compliance as a deal asset framed something we argue about internally: whether billing and coding cleanup is a genuine value-creation lever post-close or only downside protection. We're mapping the RCM layer underneath PPM and DSO roll-ups and would value 20 minutes on what you're seeing in structures and buyer appetite this cycle, no live mandate, just calibration before we commit capital. Happy to work around your conference schedule. Would a call in the next two weeks work? Best, [Your Name]

Linked companies

Sources